PDCD6IP

Across TCGA pan-cancer cohorts, PDCD6IP mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDCD6IP data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PDCD6IP mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PDCD6IP expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

GBM, PDAC, and HNSC are the cancer types where PDCD6IP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.255	0.549	.005	16	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	15	view →
HNSC	DFS	Quartile	III,IV	1.000	0.774	.030	9	view →
CCRCC	OS	Median	IV	1.000	0.202	.034	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDCD6IP–GBM (OS)

Open the GBM breakdown →